3 Big Advantages Novavax Has Over Moderna

Moderna (NASDAQ: MRNA) just might win FDA emergency use authorization for its COVID-19 vaccine candidate mRNA-1273 by the end of the year. Only one other coronavirus vaccine even has a chance of doing so. If mRNA-1273 is successful, Moderna stands to receive billions of dollars thanks to multiple supply deals that the company has lined up.

Meanwhile, Novavax (NASDAQ: NVAX) has yet to begin its anticipated U.S. late-stage study of its COVID-19 vaccine candidate. But if you're thinking that this puts Moderna and Novavax in completely different leagues, think again. Actually, there are three big advantages that Novavax has over Moderna.

Image source: Getty Images.

Source Fool.com